Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 17, 2017

Study Completion Date

March 14, 2019

Conditions
Cancer
Interventions
PROCEDURE

Bone scan

Scan to diagnose a number of bone conditions including cancer or metastasis

DRUG

99mTc-methyl diphosphonate

Radiolabel for bone scan procedures

PROCEDURE

Positron Emission Tomography (PET) scan

Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

DRUG

18F-Fludeoxyglucose (18F-FDG)

Radiolabel for positron emission tomography scan procedures

PROCEDURE

Computed Tomography (CT) scan

Scan to detect \& analyze X-rays

DRUG

18F-Sodium Fluoride (18F-NaF)

Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.

PROCEDURE

Whole Body Magnetic Resonance Imaging (WB-MRI) scan

Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.

DRUG

Gadopentetate dimeglumine

A gadolinium-based contrast agent for MRI

DRUG

Gadofosveset

A gadolinium-based contrast agent for MRI

DRUG

Gadobutrol

A gadolinium-based contrast agent for MRI

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00375830 - Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases | Biotech Hunter | Biotech Hunter